Dr. Agarwal's Health Care Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Latest quarter profit grew 64.9% YoY, showing strong momentum
- Company has delivered good sales growth of 41.0% CAGR over last 5 years
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 8.78x)
- Working capital cycle has improved - days down from 100 to -0
CONS
- Recent results are weak - TTM profit is down 48.5% versus prior year
- A large part of profit comes from other income (59.6% of PBT)
- Company has a low return on equity of 2.0% over last 3 years
- Company has a low return on capital employed of 8.3%
- Interest coverage is weak at 1.8x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | 8850.00 | 60.90 | 127249.42 | 0.23 | 610.40 | 38.41 | 7043.50 | 20.56 | 21.73 | 15.70 |
| MAXHEALTH | 1037.20 | 69.29 | 100951.74 | 0.19 | 322.96 | 4.87 | 2366.17 | 16.70 | 14.97 | 25.29 |
| MANIPALHOS | 716.15 | 105.57 | 94200.74 | 0.00 | 2434.30 | — | 30906.30 | — | 13.93 | 23.83 |
| FORTIS | 887.30 | 63.93 | 66987.44 | 0.11 | 272.80 | 2.26 | 2545.03 | 17.46 | 14.07 | 21.28 |
| ASTERDM | 762.95 | 208.69 | 66504.25 | 0.39 | 29.28 | -68.70 | 1310.68 | 21.60 | 11.26 | 19.53 |
| MEDANTA | 1447.55 | 69.98 | 38920.53 | 0.03 | 157.25 | -1.09 | 1304.05 | 26.50 | 19.38 | 21.99 |
| NH | 1867.35 | 46.76 | 38161.31 | 0.24 | 207.27 | 5.37 | 2683.63 | 78.05 | 16.20 | 17.43 |
| KIMS | 768.85 | 158.06 | 32292.20 | 0.00 | 37.40 | -56.00 | 1179.50 | 35.33 | 11.51 | 19.03 |
| LALPATHLAB | 1909.40 | 59.14 | 32049.05 | 1.07 | 1705.00 | 1172.39 | 7977.00 | 1090.95 | 29.56 | 31.03 |
| AGARWALEYE | 507.00 | 108.33 | 16073.23 | 0.00 | 55.02 | 44.56 | 614.02 | 25.97 | 16.14 | 27.75 |
| VIJAYA | 1502.30 | 82.53 | 15473.35 | 0.13 | 53.10 | 37.61 | 230.98 | 22.83 | 30.28 | 42.66 |
| RAINBOW | 1443.40 | 51.37 | 14660.13 | 0.24 | 62.54 | 16.23 | 469.99 | 33.17 | 28.25 | 28.65 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 213 | 225 | 240 | 255 | 268 | 281 | 302 | 309 | 335 | 348 | 383 | |
| 158 | 157 | 190 | 198 | 203 | 208 | 235 | 240 | 255 | 256 | 364 | |
| Operating Profit | 55 | 67 | 49 | 58 | 65 | 73 | 67 | 69 | 80 | 92 | 19 |
| OPM % | 25.91% | 30.02% | 20.53% | 22.62% | 24.15% | 26.13% | 22.14% | 22.29% | 23.90% | 26.41% | 4.99% |
| 13 | 13 | 2 | 5 | 10 | 24 | 12 | 6 | 6 | 1 | 3 | |
| Interest | 22 | 22 | 23 | 23 | 23 | 21 | 19 | 17 | 18 | 19 | 19 |
| Depreciation | 32 | 35 | 37 | 38 | 39 | 42 | 44 | 48 | 48 | 56 | 58 |
| Profit before Tax | 15 | 24 | -8 | 1 | 12 | 34 | 16 | 10 | 20 | 18 | 22 |
| Tax % | 37.11% | 29.29% | -4.93% | 745.61% | 37.02% | 22.14% | 35.19% | 51.05% | 31.08% | 42.42% | 25.91% |
| Net Profit | 10 | 17 | -9 | -4 | 8 | 27 | 10 | 5 | 14 | 11 | 17 |
| 0.34 | 0.60 | -0.30 | -0.13 | 0.25 | 0.85 | 0.32 | 0.15 | 0.44 | 0.33 | 0.53 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 248 | 232 | 362 | 598 | 835 | 1,044 | 1,293 | 1,374 | |
| 202 | 199 | 275 | 438 | 615 | 803 | 986 | 1,114 | |
| Operating Profit | 46 | 33 | 86 | 160 | 220 | 241 | 307 | 260 |
| OPM % | 18.54% | 14.18% | 23.82% | 26.70% | 26.35% | 23.10% | 23.74% | 18.91% |
| 9 | 4 | 10 | -9 | 42 | 47 | 31 | 17 | |
| Interest | 42 | 34 | 38 | 64 | 88 | 94 | 77 | 73 |
| Depreciation | 49 | 55 | 59 | 92 | 129 | 156 | 197 | 210 |
| Profit before Tax | -36 | -52 | -1 | -6 | 45 | 39 | 64 | 71 |
| Tax % | -0.00% | -3.63% | -54.74% | 640.92% | 46.64% | 43.19% | 38.32% | 35.08% |
| Net Profit | -36 | -54 | -1 | 32 | 24 | 22 | 39 | 46 |
| EPS | -51.99 | -78.83 | -2.15 | 1.34 | 25.54 | 0.69 | 1.25 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 41%
- 3 Years:
- 29%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 8%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 19%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 3%
- 3 Years:
- 2%
- Last Year:
- 2%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 8 | 9 | 32 | 32 |
| 248 | 194 | 192 | 552 | 1,212 | 1,892 | 1,948 | |
| 266 | 365 | 394 | 610 | 692 | 554 | 650 | |
| Trade Payables | 41 | 51 | 54 | 60 | 84 | 80 | 99 |
| 35 | 26 | 46 | 119 | 171 | 278 | 256 | |
| Total Liabilities | 596 | 643 | 692 | 1,349 | 2,169 | 2,836 | 2,984 |
| 322 | 387 | 367 | 907 | 1,302 | 1,591 | 1,922 | |
| Capital Work in Progress | 3 | 11 | 2 | 35 | 9 | 16 | 29 |
| 146 | 121 | 147 | 187 | 629 | 729 | 615 | |
| 15 | 12 | 18 | 20 | 30 | 47 | 54 | |
| 0 | 0 | 0 | 0 | 50 | 73 | 83 | |
| Cash & Bank | 29 | 33 | 60 | 97 | 63 | 188 | 73 |
| 80 | 79 | 99 | 101 | 87 | 191 | 208 | |
| Total Assets | 596 | 643 | 692 | 1,349 | 2,169 | 2,836 | 2,984 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 43 | 48 | 81 | 165 | 222 | 206 | 321 | |
| Cash from Investing | -37 | -26 | -98 | -436 | -818 | -577 | -167 |
| Cash from Financing | -60 | -21 | 40 | 316 | 570 | 374 | -173 |
| -56 | -1 | 20 | 33 | -26 | 2 | -19 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-29 - Dr. Agarwal's Health Care Limited has informed the Exchange about Copy of Newspaper Publication regarding the Sixteenth Annual General Meeting of the Company, Instructions for e-Voting and Other Related Information
2026-08-28 - Notice convening the Sixteenth Annual General Meeting of Dr. Agarwal s Health Care Limited along with the Annual Report for the Financial Year 2025-2026, is submitted
2026-08-27 - Dr. Agarwal's Health Care Limited has informed the Exchange regarding a press release dated August 27, 2026, titled "Launch of World s First Pinhole Pupilloplasty (PPP) Centre by Dr. Agarwal's Eye Hospital Limited, a subsidiary of the Company.".
2026-08-25 - Dr. Agarwal's Health Care Limited has informed the Exchange about Schedule of meet
2026-08-07 - Dr. Agarwal's Health Care Limited has informed the Exchange about Transcript
2026-08-04 - Dr. Agarwal's Health Care Limited has informed the Exchange about Link of Recording
2026-08-04 - Dr. Agarwal's Health Care Limited - Monitoring Agency Report for the quarter ended June 30, 2026, is attached.
2026-08-04 - Dr. Agarwal's Health Care Limited has informed the Exchange about Investor Presentation
2026-08-04 - Board Meeting Outcome for Consolidated And Standalone Unaudited Financial Results For The Quarter Ended June 30, 2026 And Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
News
Recent coverage and analyst commentary for AGARWALEYE
Loading news…
AI Stock Analyst
Dr. Agarwal's Health Care Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account